A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Buparlisib (Primary)
- Indications Breast cancer; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Dec 2012 Planned end date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 18 Dec 2012 New trial record